GO
Loading...

Enter multiple symbols separated by commas

Biotech and Pharmaceuticals

More

  • A hot biotech that may be the next Genentech Tuesday, 12 May 2015 | 7:00 AM ET
    Biotech

    This company has raised $1 billion to develop the Holy Grail in drugs: Have the body's own cells churn out proteins to fight disease.

  • EU animal research ban could ‘damage prosperity’ Monday, 11 May 2015 | 10:26 AM ET

    European lawmakers to debate scrapping animal testing, a move which could spell trouble for the pharma industry, experts have warned.

  • GSK, US experts team up to find cure for AIDS Monday, 11 May 2015 | 9:22 AM ET
    AIDS, HIV, Africa

    Britain's GlaxoSmithKline is to collaborate with U.S. scientists in developing a cure for AIDS.

  • The right to try test drugs gets more transparent Thursday, 7 May 2015 | 3:57 PM ET
    An employee processes solutions containing samples taken from hazard suits and clothing to detect evidence of contamination in a laboratory at the Bavarian Nordic A/S biotechnology company.

    A development in how patient requests for experimental drugs are handled could be a big step in health care, said a medical director Thursday.

  • Is biotech in a bubble?   Thursday, 7 May 2015 | 8:04 AM ET
    Is biotech in a bubble?

    Top-rated biotech analyst Mark Schoenebaum weighs in on latest mega-deal & bubble talk.

  • J&J opens door for more use of trial drugs Thursday, 7 May 2015 | 6:17 AM ET
    Arthur Caplan, Bioethicist

    Johnson & Johnson will become the first pharmaceutical company to formally seek advice from outside medical ethicists on "compassionate use" requests.

  • London biotech market historically tough: CEO   Thursday, 7 May 2015 | 4:40 AM ET
    London biotech market historically tough: CEO

    Ali Mortazavi, CEO at Silence Therapeutics, discusses the difficulties in tackling the biotech space.

  • Booming biotech: Alexion buys Synageva   Thursday, 7 May 2015 | 4:40 AM ET
    Booming biotech: Alexion buys Synageva

    Alexion has acquired Synageva Biopharma for over $8.4 billion. Ali Mortazavi, CEO at Silence Therapeutics, discusses possible reasons behind the deal.

  • Alexion to buy Synageva   Wednesday, 6 May 2015 | 4:20 PM ET
    Alexion to buy Synageva

    Alexion's acquisition of Synageva is valued at $8.4 billion in cash and stock, reports CNBC's Meg Tirrell. Tom Lyndon, ETFtrends.com, discusses M&A trends in the biotech space.

  • GSK's new strategy   Wednesday, 6 May 2015 | 1:17 PM ET
    GSK's new strategy

    GlaxoSmithKline outlined its business strategy for the next four years. Insight, with CNBC's Meg Tirrell.

  • Another mega deal in biotech   Wednesday, 6 May 2015 | 12:13 PM ET
    Another mega deal in biotech

    IS biotech in a bubble? Mark Schoenebaum, Evercore ISI Analyst, discusses talk on Alexion to buy Synageva.

  • Two pharma giants merge in $8.4B deal Wednesday, 6 May 2015 | 8:01 AM ET
    Pharmaceuticals

    Alexion said it would buy Synageva for $8.4 billion to gain access to its experimental early-stage treatment for a rare metabolic disease.

  • Spending on this type of meds hit a new milestone Tuesday, 5 May 2015 | 12:01 AM ET
    Employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    That's up more than 10 percent from 2013 and up from $75 billion five years earlier, according to a new report.

  • Sarissa Capital's biotech bets   Monday, 4 May 2015 | 11:25 AM ET
    Sarissa Capital's biotech bets

    Alex Denner, Sarissa Capital Management founder, discusses the opportunity in ARIAD Pharmaceuticals.

  • Biotech's torrid run may not be over, analyst says Friday, 1 May 2015 | 3:40 PM ET
    Biotech pharmaceuticals

    Biotech's "great run" will continue despite a bumpy April, which came on the heels of a big jump in the sector, one analyst said.

  • Biotech's big outlook   Friday, 1 May 2015 | 2:09 PM ET
    Biotech's big outlook

    Corey Davis, Canaccord Genuity, says Gilead's earnings put a floor in the biotech space.

  • Are leveraged ETFs making biotech stocks sick? Friday, 1 May 2015 | 12:05 PM ET
    Biotech

    Jon Najarian, co-founder of OptionMonster.com, breaks down a worrisome trend in the stock market right now.

  • Unicorn plans to push diabetes drugs   Friday, 1 May 2015 | 11:17 AM ET
    Unicorn plans to push diabetes drugs

    Intarcia Therapeutics Inc. said it raised $225 million in the latest in a series of financing to support the development of its implantable drug-delivery pump for patients with diabetes.Kurt Graves, Intarcia Therapeutics chairman and CEO, discusses.

  • Tough month for biotech   Friday, 1 May 2015 | 5:00 AM ET
    Tough month for biotech

    Carter Worth, head of technical analysis at Cornerstone Macro, talks U.S. stocks, including biotech, and what to expect in the month of May.

  • Biotech bunking together   Thursday, 30 Apr 2015 | 3:46 PM ET
    Biotech bunking together

    Biotech is bunking up in Cambridge's hottest zip codes as an affordable way to be in the hotbed of research. Details, with CNBC's Meg Tirrell.

Contact Biotech and Pharma

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

 

  • Dan Mangan is a reporter covering health care for CNBC.com.

  • Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.

  • Bertha Coombs

    Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.